Molly Quinn1, Kanade Shinkai2, Lauri Pasch3, Lili Kuzmich4, Marcelle Cedars5, Heather Huddleston5. 1. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California-San Francisco School of Medicine, San Francisco, California. Electronic address: quinnm@obgyn.ucsf.edu. 2. Department of Dermatology, University of California-San Francisco School of Medicine, San Francisco, California. 3. Department of Psychiatry, University of California-San Francisco School of Medicine, San Francisco, California. 4. Cancer Risk Program, University of California-San Francisco School of Medicine, San Francisco, California. 5. Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California-San Francisco School of Medicine, San Francisco, California.
Abstract
OBJECTIVE: To describe the prevalence of androgenic alopecia (AGA) in patients with polycystic ovary syndrome (PCOS) and to characterize associated clinical and biochemical features. DESIGN: Cross-sectional study. SETTING: Multidisciplinary PCOS clinic at a tertiary academic center. PATIENT(S): A total of 254 women with PCOS according to the Rotterdam criteria were systematically examined from 2007 to 2012 by a reproductive endocrinologist, a dermatologist, and a psychologist. INTERVENTION(S): Comprehensive dermatologic exams, ultrasonic imaging, serum testing, and Beck Depression Inventory Fast Screen (BDI-FS). MAIN OUTCOME MEASURES: Presence of AGA, acne, hirsutism, biochemical hyperandrogenemia, metabolic dysfunction, and clinical depression. RESULT(S): Fifty-six of 254 patients with PCOS (22.0%) had AGA. Subjects with PCOS and AGA were more likely to have acne or hirsutism than those without AGA (96.3% vs. 70.6%). Subjects with AGA were more likely to report concern with hair loss (70.4% vs. 37.7%); however, their BDI-FS scores were no different from subjects without AGA. There were no differences between subjects with and without AGA in biochemical hyperandrogenism or metabolic parameters. CONCLUSION(S): AGA is prevalent in 22% of subjects meeting diagnostic criteria for PCOS. AGA is associated with other manifestations of clinical hyperandrogenism, but not with greater risk of biochemical hyperandrogenemia or metabolic dysfunction than with PCOS alone.
OBJECTIVE: To describe the prevalence of androgenic alopecia (AGA) in patients with polycystic ovary syndrome (PCOS) and to characterize associated clinical and biochemical features. DESIGN: Cross-sectional study. SETTING:Multidisciplinary PCOS clinic at a tertiary academic center. PATIENT(S): A total of 254 women with PCOS according to the Rotterdam criteria were systematically examined from 2007 to 2012 by a reproductive endocrinologist, a dermatologist, and a psychologist. INTERVENTION(S): Comprehensive dermatologic exams, ultrasonic imaging, serum testing, and Beck Depression Inventory Fast Screen (BDI-FS). MAIN OUTCOME MEASURES: Presence of AGA, acne, hirsutism, biochemical hyperandrogenemia, metabolic dysfunction, and clinical depression. RESULT(S): Fifty-six of 254 patients with PCOS (22.0%) had AGA. Subjects with PCOS and AGA were more likely to have acne or hirsutism than those without AGA (96.3% vs. 70.6%). Subjects with AGA were more likely to report concern with hair loss (70.4% vs. 37.7%); however, their BDI-FS scores were no different from subjects without AGA. There were no differences between subjects with and without AGA in biochemical hyperandrogenism or metabolic parameters. CONCLUSION(S): AGA is prevalent in 22% of subjects meeting diagnostic criteria for PCOS. AGA is associated with other manifestations of clinical hyperandrogenism, but not with greater risk of biochemical hyperandrogenemia or metabolic dysfunction than with PCOS alone.
Authors: Sara Pittenger Reid; Chia-Ning Kao; Lauri Pasch; Kanade Shinkai; Marcelle I Cedars; Heather G Huddleston Journal: Fertil Res Pract Date: 2017-05-30
Authors: Felix Day; Tugce Karaderi; Michelle R Jones; Cindy Meun; Chunyan He; Alex Drong; Peter Kraft; Nan Lin; Hongyan Huang; Linda Broer; Reedik Magi; Richa Saxena; Triin Laisk; Margrit Urbanek; M Geoffrey Hayes; Gudmar Thorleifsson; Juan Fernandez-Tajes; Anubha Mahajan; Benjamin H Mullin; Bronwyn G A Stuckey; Timothy D Spector; Scott G Wilson; Mark O Goodarzi; Lea Davis; Barbara Obermayer-Pietsch; André G Uitterlinden; Verneri Anttila; Benjamin M Neale; Marjo-Riitta Jarvelin; Bart Fauser; Irina Kowalska; Jenny A Visser; Marianne Andersen; Ken Ong; Elisabet Stener-Victorin; David Ehrmann; Richard S Legro; Andres Salumets; Mark I McCarthy; Laure Morin-Papunen; Unnur Thorsteinsdottir; Kari Stefansson; Unnur Styrkarsdottir; John R B Perry; Andrea Dunaif; Joop Laven; Steve Franks; Cecilia M Lindgren; Corrine K Welt Journal: PLoS Genet Date: 2018-12-19 Impact factor: 6.020